Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234676 · ClinicalTrials.gov registry record · Phase 2
POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease
A Phase 2 study of Parkinson's Disease, sponsored by The Parkinson Study Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 6
- Study locations
NCT00234676: Completed Phase 2 study of Parkinson's Disease, sponsored by The Parkinson Study Group.
NCT00234676 is a Phase 2 study of Parkinson's Disease that has completed, run by The Parkinson Study Group. The registered enrollment target is 23 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00234676, a Phase 2 study of Parkinson's Disease, has completed, sponsored by The Parkinson Study Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary objectives of the POETRY study are to assess the safety and tolerability of estrogen replacement therapy (ERT) in postmenopausal women with Parkinson's disease (PD) and to assess recruitment for a study of ERT in postmenopausal women with PD.
Conditions Studied
Interventions
- DRUG Premarin ®
Study Locations (6)
California
- The Parkinson's Institute - Sunnyvale
Georgia
- Emory University - Atlanta
Indiana
- Indiana University School of Medicine - Indianapolis
Maryland
- University of Maryland - Baltimore
New York
- University of Rochester - Rochester
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
What the finished NCT00234676 record still lists
NCT00234676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Premarin ® is the first listed.
NCT00234676 lists 6 locations in 6 states (California, Georgia, Indiana).
Frequently Asked Questions
What is clinical trial NCT00234676 about?
NCT00234676 is a clinical study titled "POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease". The primary objectives of the POETRY study are to assess the safety and tolerability of estrogen replacement therapy (ERT) in postmenopausal women with Parkinson's disease (PD) and to assess recruitment for a study of ERT in postmenopausal women with PD.
What is the current status of trial NCT00234676?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2003-10. Estimated completion is 2006-03.
What conditions does trial NCT00234676 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00234676?
The interventions under investigation include: Premarin ® (DRUG).
Who is sponsoring clinical trial NCT00234676?
This trial is sponsored by The Parkinson Study Group, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00234676 being conducted?
This trial has 6 study locations across California, Georgia, Indiana, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00234676's enrollment target sits among peer trials
23 122nd of 158 higher than 35 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia